These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 24046769)

  • 1. The role of type 1 interferon in systemic sclerosis.
    Wu M; Assassi S
    Front Immunol; 2013 Sep; 4():266. PubMed ID: 24046769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I interferon dysregulation in Systemic Sclerosis.
    Skaug B; Assassi S
    Cytokine; 2020 Aug; 132():154635. PubMed ID: 30685202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting interferons as a strategy for systemic sclerosis treatment.
    Ciechomska M; Skalska U
    Immunol Lett; 2018 Mar; 195():45-54. PubMed ID: 29106987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis.
    Liu X; Mayes MD; Tan FK; Wu M; Reveille JD; Harper BE; Draeger HT; Gonzalez EB; Assassi S
    Arthritis Rheum; 2013 Jan; 65(1):226-35. PubMed ID: 23055137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis.
    Brkic Z; van Bon L; Cossu M; van Helden-Meeuwsen CG; Vonk MC; Knaapen H; van den Berg W; Dalm VA; Van Daele PL; Severino A; Maria NI; Guillen S; Dik WA; Beretta L; Versnel MA; Radstake T
    Ann Rheum Dis; 2016 Aug; 75(8):1567-73. PubMed ID: 26371289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic sclerosis and lupus: points in an interferon-mediated continuum.
    Assassi S; Mayes MD; Arnett FC; Gourh P; Agarwal SK; McNearney TA; Chaussabel D; Oommen N; Fischbach M; Shah KR; Charles J; Pascual V; Reveille JD; Tan FK
    Arthritis Rheum; 2010 Feb; 62(2):589-98. PubMed ID: 20112391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Long Non-coding RNA NRIR Drives IFN-Response in Monocytes: Implication for Systemic Sclerosis.
    Mariotti B; Servaas NH; Rossato M; Tamassia N; Cassatella MA; Cossu M; Beretta L; van der Kroef M; Radstake TRDJ; Bazzoni F
    Front Immunol; 2019; 10():100. PubMed ID: 30804934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.
    Farina A; Peruzzi G; Lacconi V; Lenna S; Quarta S; Rosato E; Vestri AR; York M; Dreyfus DH; Faggioni A; Morrone S; Trojanowska M; Farina GA
    Arthritis Res Ther; 2017 Feb; 19(1):39. PubMed ID: 28245863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.
    Lande R; Mennella A; Palazzo R; Pietraforte I; Stefanantoni K; Iannace N; Butera A; Boirivant M; Pica R; Conrad C; Chizzolini C; Riccieri V; Frasca L
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis.
    Dieudé P; Guedj M; Wipff J; Ruiz B; Hachulla E; Diot E; Granel B; Sibilia J; Tiev K; Mouthon L; Cracowski JL; Carpentier PH; Amoura Z; Fajardy I; Avouac J; Meyer O; Kahan A; Boileau C; Allanore Y
    Arthritis Rheum; 2009 Aug; 60(8):2472-9. PubMed ID: 19644887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis.
    Arismendi M; Giraud M; Ruzehaji N; Dieudé P; Koumakis E; Ruiz B; Airo P; Cusi D; Matucci-Cerinic M; Salvi E; Cuomo G; Hachulla E; Diot E; Caramaschi P; Riccieri V; Avouac J; Kayser C; Allanore Y
    Arthritis Res Ther; 2015 Mar; 17(1):71. PubMed ID: 25880423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Inhibition of IRF-Dependent Transcriptional Regulatory Mechanisms Associated With Disease.
    Antonczyk A; Krist B; Sajek M; Michalska A; Piaszyk-Borychowska A; Plens-Galaska M; Wesoly J; Bluyssen HAR
    Front Immunol; 2019; 10():1176. PubMed ID: 31178872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulation of Type 1 Interferon Signaling in Systemic Sclerosis: a Promising Therapeutic Target?
    Wu M; Assassi S
    Curr Treatm Opt Rheumatol; 2021 Dec; 7(4):349-360. PubMed ID: 35694218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What does global gene expression profiling tell us about the pathogenesis of systemic sclerosis?
    Assassi S; Mayes MD
    Curr Opin Rheumatol; 2013 Nov; 25(6):686-91. PubMed ID: 24061076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma?
    Coelho LF; de Oliveira JG; Kroon EG
    Immunol Lett; 2008 Jun; 118(2):110-5. PubMed ID: 18499269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis.
    Bodewes ILA; Huijser E; van Helden-Meeuwsen CG; Tas L; Huizinga R; Dalm VASH; van Hagen PM; Groot N; Kamphuis S; van Daele PLA; Versnel MA
    J Autoimmun; 2018 Jul; 91():97-102. PubMed ID: 29673738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of type I interferons and innate immunity in systemic sclerosis: unbalanced activities on distinct cell types?
    Barrat FJ; Lu TT
    Curr Opin Rheumatol; 2019 Nov; 31(6):569-575. PubMed ID: 31436583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis.
    Rudnik M; Rolski F; Jordan S; Mertelj T; Stellato M; Distler O; Blyszczuk P; Kania G
    Arthritis Rheumatol; 2021 Sep; 73(9):1720-1730. PubMed ID: 33760395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit.
    Kakkar V; Assassi S; Allanore Y; Kuwana M; Denton CP; Khanna D; Del Galdo F
    Curr Opin Rheumatol; 2022 Nov; 34(6):357-364. PubMed ID: 36125916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.